Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2019

Summary

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 17 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Immunology, Metabolic Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Bipolar Disorder (Manic Depression), Pain, Parkinson's Disease, Smoking Addiction, Traumatic Brain Injury, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Cough, Cognitive Disorders, Cognitive Impairment, Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer's Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Neuropathic Pain (Neuralgia), Obesity, Panic Disorders and Post-Traumatic Stress Disorder (PTSD).

The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2019, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
Bionomics Ltd
Bristol-Myers Squibb Co
CoMentis Inc
DanPET AB
Epigen Biosciences Inc
Johnson & Johnson
Katexco Pharmaceuticals Corp
Merck & Co Inc
Neuro Bio Ltd
SK Biopharmaceuticals Co Ltd
Vanda Pharmaceuticals Inc
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bradanicline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gln-1062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTS-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-39393406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-12877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-20540 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize CB1, CB2 and CHRNA7 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VQW-765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
Featured News & Press Releases
Feb 19, 2019: Bionomics reports additional data from RESTORE trial
Dec 11, 2018: Bionomics receives over $6.5m R&D tax incentive refund
Nov 14, 2018: Attenua announces first patient treated in phase 2 clinical trial in Chronic Cough with Bradanicline
Oct 02, 2018: Bionomics phase 2 post traumatic stress disorder trial results
Sep 04, 2018: Bionomics to host KOL call focused on BNC210 and the treatment of agitation in elderly patients
Jul 27, 2018: Bionomics Presents at the 14th Annual Bioshares Biotech Summit
Jul 09, 2018: End-Of-Treatment Milestone Met In The Phase 2 Clinical Trial Of BNC210 For The Treatment Of PTSD
May 23, 2018: Bionomics: Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation
Apr 11, 2018: Phase 2 Clinical Trial of BNC210 For Treatment of Post traumatic Stress Disorder Fully Recruited
Apr 06, 2018: Bionomics To Host KOL Meetings Focused On BNC210 And The Treatment Of PTSD In New York And London
Dec 19, 2017: Neurodyn Appoints Anthony J. Giovinazzo as Director and Executive Chairman
Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs
Sep 01, 2017: Bionomics BNC210 to Feature at the 30th ECNP Congress
Aug 21, 2017: Bionomics & MSD 5th Annual Neuroscience Symposium in October
Jul 21, 2017: Bionomics Presents at 13th Annual Bioshares Biotech Summit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer